<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>There was no overall increase in PB-CFU-GM from <z:mpath ids='MPATH_458'>normal</z:mpath> subjects, or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients, when exogenous CSA (5637-CM) was added to the culture medium </plain></SENT>
<SENT sid="1" pm="."><plain>However, there was a sub-group of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients (seven of 35) whose PB-CFU-GM numbers were significantly stimulated by 5637-CM </plain></SENT>
<SENT sid="2" pm="."><plain>In addition, there were 11 (out of 48) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with undetectable PB-CFU-GM in assays without exogenous CSA but only two when 5637-CM was added (p less than 0.01) </plain></SENT>
<SENT sid="3" pm="."><plain>This sub-group is of particular interest as it is known that those without detectable PB-CFU-GM tend to have significantly shorter survival times than others </plain></SENT>
<SENT sid="4" pm="."><plain>The mechanism of the functional abnormality is yet to be determined </plain></SENT>
</text></document>